<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210208</url>
  </required_header>
  <id_info>
    <org_study_id>MpT Ag 03</org_study_id>
    <nct_id>NCT02210208</nct_id>
  </id_info>
  <brief_title>An Open, Non Controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.</brief_title>
  <acronym>MpT Ag 03</acronym>
  <official_title>An Open, Non Controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, non controlled, multi-centre, clinical investigation to verify performance and
      safety of a soft silicone wound contact layer containing silver in the treatment of skin
      grafts in surgical burn patients and the usefulness of a marketed donor site dressing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing</measure>
    <time_frame>14 days</time_frame>
    <description>Adequate take of skin graft (defined as at least 95% adherent and healed as assessed by clinical investigator)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Skin Grafts in Surgical Burn Patients.</condition>
  <arm_group>
    <arm_group_label>Mepitel Ag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mepitel Ag treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepitel Ag</intervention_name>
    <arm_group_label>Mepitel Ag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A

        Inclusion Criteria

          -  Subjects with burn injury resulting in up to 30% TBSA

          -  Full thickness area of burn should not be more than 20%

          -  Area in need of skin grafting can be 1-15% TBSA

          -  Study site area must have healthy, intact peri-wound skin surrounding it to allow for
             adequate overlap of study product

          -  Thermal injuries only

          -  Subjects age 18 months to &lt; 65 years.

          -  Signed informed consent

          -  Subjects who are younger than the legal consenting age must in addition to their own
             assent form have a signature from a legally authorized representative.

        Exclusion Criteria

          -  Greater than 30% TBSA

          -  Full thickness areas greater than 20% TBSA

          -  Full thickness area to be grafted less than 1%

          -  Presence of respiratory involvement

          -  Subjects on mechanical ventilation

          -  Subjects with infected burn wounds

          -  Subjects with organ failure

          -  Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe aeaemia) judged by
             the investigator to be a potential interference in the treatment

          -  Subjects treated with systemic glucocorticosteroids, except patients taking
             occasional doses or doses less than 10mg prednisolone/day or equivalent

          -  Known allergy/hypersensitivity to any of the components of the investigation
             products.

          -  Subjects with physical and/or mental conditions that are not expected to comply with
             the investigation, including patients totally confined to bed

          -  Participation in other clinical investigation(s) within 1 month prior to start of the
             investigation

          -  Previous randomized to this investigation

        Part B

        Inclusion Criteria

        -There must be healthy, intact peri-wound skin surrounding the planned donor site to allow
        for adequate overlap of study product (5 cm)

        Exclusion Criteria

          -  Investigator do not agree to treat the donor site with Mepilex Transfer Ag

          -  The subject do not agree to participate in the donor site part
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Glat, Doctor</last_name>
    <phone>215-427-5191</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The Arizona Burn Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Foster, Dr</last_name>
      <email>Kevin_Foster@dmgaz.org</email>
    </contact>
    <contact_backup>
      <last_name>Renee Robles_Schein, Coordinator</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of South Florida Board of Trustees</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32886-4687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Plastic Surgical Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Riina, MD</last_name>
      <email>lriina@mac.com</email>
    </contact>
    <investigator>
      <last_name>Louis Riina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Chrisopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA 19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Glat, Doctor</last_name>
      <phone>215-427-5191</phone>
    </contact>
    <investigator>
      <last_name>Paul Glat, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 22, 2016</lastchanged_date>
  <firstreceived_date>August 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
